

## RESULTS OF ANNUAL GENERAL MEETING

**Melbourne, Australia – 22 October 2025:** Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s Annual General Meeting of shareholders.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the Annual General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the Annual General Meeting.

All resolutions to be voted on at the meeting were decided on a poll.

As more than 75% of votes cast on Resolution 1 supported the adoption of the 2025 Remuneration Report, Resolution 7 (the Conditional Spill Resolution) was withdrawn

The Board thanks shareholder for their attendance and participation at the Annual General Meeting.

---

### About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at [www.PercheronTx.com](http://www.PercheronTx.com), or email [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors.*

---

**Percheron Therapeutics Limited**  
**Annual General Meeting**  
**Wednesday, 22 October 2025**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of the 2025 Remuneration Report (non-binding)	Ordinary	243,924,127 78.69%	45,241,387 14.60%	20,803,602 6.71%	791,419	264,727,729 85.40%	45,241,387 14.60%	791,419	Carried	NO
2. Re-Election of Director – Dr Charmaine Gittleson	Ordinary	321,705,380 96.16%	572,845 0.17%	12,258,263 3.66%	37,776,546	333,963,643 99.83%	572,845 0.17%	37,776,546	Carried	N/A
3. Ratification of Prior Issue of Tranche 2 Shares to Institutional Investors	Ordinary	282,914,880 90.50%	7,696,466 2.46%	21,995,238 7.04%	507,150	304,910,118 97.54%	7,696,466 2.46%	507,150	Carried	N/A
4. Approval of 10% Placement Facility (special resolution)	Special	304,418,234 82.05%	45,511,048 12.27%	21,103,602 5.69%	1,280,150	325,521,836 87.73%	45,511,048 12.27%	1,280,150	Carried	N/A
5. Amendments to Constitution (special resolution)	Special	304,919,689 82.03%	44,927,357 12.09%	21,880,238 5.89%	585,750	326,799,927 87.91%	44,927,357 12.09%	585,750	Carried	N/A
6. Re-insertion of Proportional Takeover Bid Approval Provisions (special resolution)	Special	313,669,492 84.41%	36,777,854 9.90%	21,139,938 5.69%	725,750	334,809,430 90.10%	36,777,854 9.90%	725,750	Carried	N/A
7. Spill Resolution (conditional resolution)	Ordinary	45,414,563 14.66%	254,725,476 82.22%	9,653,346 3.12%	967,150	Resolution 7 - Spill Resolution has been			WITHDRAWN	

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.